An Investigation on a Novel Anti-tumor Fusion Peptide of FSH33-53-IIKK

Runlin Yang; Ping Liu; Donghui Pan; Pengjun Zhang; Zhicheng Bai; Yuping Xu; Lizhen Wang; Junjie Yan; Yongjun Yan; Xingdang Liu; Min Yang

doi:10.7150/jca.14425

An Investigation on a Novel Anti-tumor Fusion Peptide of FSH33-53-IIKK

J Cancer. 2016 May 24;7(8):1010-9. doi: 10.7150/jca.14425. eCollection 2016.

Authors

Runlin Yang¹, Ping Liu², Donghui Pan¹, Pengjun Zhang², Zhicheng Bai³, Yuping Xu¹, Lizhen Wang¹, Junjie Yan¹, Yongjun Yan⁴, Xingdang Liu⁵, Min Yang⁶

Affiliations

¹ 1. Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, China.
² 2. School of Pharmaceutical Science, Zhengzhou University, Zhengzhou 450000, China.
³ 3. The First School of Clinical Medicine, Nanjing Medical University, Nanjing 210029, China.
⁴ 4. Department of Medical Physics, University of Wisconsin, Madison, WI 53705, USA.
⁵ 5. Department of Nuclear Medicine, Hua Shan Hospital, Fudan University, Shanghai 200040, China.
⁶ 1. Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, China.; 2. School of Pharmaceutical Science, Zhengzhou University, Zhengzhou 450000, China.; 3. The First School of Clinical Medicine, Nanjing Medical University, Nanjing 210029, China.

Abstract

A novel fusion peptide FSH33-53-IIKK was designed and expected to combine the follicle stimulating hormone receptor (FSHR) targeting and tumor toxicity. In vitro and in vivo study showed the anti-tumor activity of FSH33-53-IIKK was enhanced compared to that of IIKK only. FSH33-53-IIKK could inhibit the growth of tumor via apoptosis and autophagy pathways. In summary, combining the tumor marker-target peptide and anti-tumor peptide together may be an efficient way to search for better anti-tumor candidates.

Keywords: Anti-tumor; Apoptosis; Autophagy; FSH33-53-IIKK; FSHR; Fusion peptide.